243 related articles for article (PubMed ID: 34043023)
1. Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy.
Liu Y; Long W; Zhang Z; Zhang Z; Mai L; Huang S; Han H; Zhou F; Dong P; He L
World J Urol; 2021 Nov; 39(11):4183-4190. PubMed ID: 34043023
[TBL] [Abstract][Full Text] [Related]
2. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
[TBL] [Abstract][Full Text] [Related]
3. The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma.
Onal C; Hurmuz P; Guler OC; Yavas G; Tilki B; Oymak E; Yavas C; Ozyigit G
Clin Transl Oncol; 2022 Aug; 24(8):1533-1541. PubMed ID: 35119653
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic Body Radiotherapy for Stage I Renal Cell Carcinoma: National Treatment Trends and Outcomes Compared to Partial Nephrectomy and Thermal Ablation.
Uhlig A; Uhlig J; Trojan L; Kim HS
J Vasc Interv Radiol; 2020 Apr; 31(4):564-571. PubMed ID: 32127324
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study.
Onal C; Oymak E; Guler OC; Tilki B; Yavas G; Hurmuz P; Yavas C; Ozyigit G
Strahlenther Onkol; 2023 May; 199(5):456-464. PubMed ID: 36450836
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
[TBL] [Abstract][Full Text] [Related]
7. Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study.
Onal C; Guler OC; Hurmuz P; Yavas G; Tilki B; Oymak E; Yavas C; Ozyigit G
Strahlenther Onkol; 2022 Oct; 198(10):940-948. PubMed ID: 35695908
[TBL] [Abstract][Full Text] [Related]
8. Treatment Outcomes of Stereotactic Body Radiotherapy in Patients with Synchronous and Metachronous Oligometastatic Renal Cell Carcinoma.
Guler OC; Oymak E; Hurmuz P; Yavas G; Tilki B; Yavas C; Ozyigit G; Onal C
Urol Int; 2023; 107(2):171-178. PubMed ID: 36455527
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
[TBL] [Abstract][Full Text] [Related]
10. Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study.
Buti S; Bersanelli M; Viansone A; Leonetti A; Masini C; Ratta R; Procopio G; Maines F; Iacovelli R; Ciccarese C; Vitale MG; De Giorgi U; Mucciarini C; Maruzzo M; Prati G; Lattanzi E; Ciammella P; Bruni A; Andreani S; D'Abbiero N
Cancer Treat Res Commun; 2020; 22():100161. PubMed ID: 31677494
[TBL] [Abstract][Full Text] [Related]
11. The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group.
Franzese C; Marvaso G; Francolini G; Borghetti P; Trodella LE; Sepulcri M; Matrone F; Nicosia L; Timon G; Ognibene L; Vinciguerra A; Alongi F; Bortolus R; Corti L; Ramella S; Magrini SM; Livi L; Jereczek-Fossa BA; Scorsetti M; Arcangeli S
Clin Exp Metastasis; 2021 Dec; 38(6):527-537. PubMed ID: 34748125
[TBL] [Abstract][Full Text] [Related]
12. Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture.
Thibault I; Al-Omair A; Masucci GL; Masson-Côté L; Lochray F; Korol R; Cheng L; Xu W; Yee A; Fehlings MG; Bjarnason GA; Sahgal A
J Neurosurg Spine; 2014 Nov; 21(5):711-8. PubMed ID: 25170656
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma.
Liu Y; Zhang Z; Liu R; Wei W; Zhang Z; Mai L; Guo S; Han H; Zhou F; He L; Dong P
Radiat Oncol; 2021 Nov; 16(1):211. PubMed ID: 34727963
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control.
Stinauer MA; Kavanagh BD; Schefter TE; Gonzalez R; Flaig T; Lewis K; Robinson W; Chidel M; Glode M; Raben D
Radiat Oncol; 2011 Apr; 6():34. PubMed ID: 21477295
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma.
Ranck MC; Golden DW; Corbin KS; Hasselle MD; Liauw SL; Stadler WM; Hahn OM; Weichselbaum RR; Salama JK
Am J Clin Oncol; 2013 Dec; 36(6):589-95. PubMed ID: 22868242
[TBL] [Abstract][Full Text] [Related]
16. Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis.
Chen X; Chen H; Poon I; Erler D; Badellino S; Biswas T; Dagan R; Foote M; Louie AV; Ricardi U; Sahgal A; Redmond KJ
Cancer Med; 2021 Sep; 10(18):6189-6198. PubMed ID: 34432390
[TBL] [Abstract][Full Text] [Related]
17. Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma.
Franzese C; Franceschini D; Di Brina L; D'Agostino GR; Navarria P; Comito T; Mancosu P; Tomatis S; Scorsetti M
J Urol; 2019 Jan; 201(1):70-76. PubMed ID: 30179619
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group.
Meyer E; Pasquier D; Bernadou G; Calais G; Maroun P; Bossi A; Theodore C; Albiges L; Stefan D; de Crevoisier R; Hennequin C; Lagrange JL; Grellard JM; Clarisse B; Licaj I; Habrand JL; Carrie C; Joly F
Eur J Cancer; 2018 Jul; 98():38-47. PubMed ID: 29864737
[TBL] [Abstract][Full Text] [Related]
19. Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT).
Altoos B; Amini A; Yacoub M; Bourlon MT; Kessler EE; Flaig TW; Fisher CM; Kavanagh BD; Lam ET; Karam SD
Radiat Oncol; 2015 Oct; 10():218. PubMed ID: 26510665
[TBL] [Abstract][Full Text] [Related]
20. Radiation Therapy for Patients with Advanced Renal Cell Carcinoma.
Miccio JA; Oladeru OT; Jun Ma S; Johung KL
Urol Clin North Am; 2020 Aug; 47(3):399-411. PubMed ID: 32600541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]